Related Experiment Videos

Progress against follicular lymphoma

Jonathan H Schatz1, Elisa Oricchio, Soham D Puvvada

  • 1Department of Medicine, University of Arizona, Tucson, Arizona, USA.

Current Opinion in Hematology
|May 16, 2013
PubMed
Abstract

Insights

Recent advances in follicular lymphoma research, including genomic studies and new therapies targeting key pathways, offer hope for improved treatments. This progress marks a significant turning point for this common, incurable lymphoma.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Follicular lymphoma (FL) is a common B-cell malignancy that remains incurable.
  • Research in FL has been limited, but recent advancements are changing this landscape.

Purpose of the Study:

  • To review recent research progress in follicular lymphoma.
  • To highlight novel therapeutic strategies and opportunities for improving FL treatment.

Main Methods:

  • Review of recent genomic studies identifying key genetic lesions in FL.
  • Introduction of a new murine model for studying FL development and treatment.
  • Evaluation of new small-molecule inhibitors targeting critical FL pathways.

Main Results:

  • Genomic studies have revealed crucial genetic drivers of FL.
  • A new murine model facilitates functional studies of FL pathogenesis and therapeutic responses.
  • Emerging small-molecule inhibitors show promise by targeting B-cell receptor signaling and histone modifiers.

Conclusions:

  • Follicular lymphoma research is advancing, revealing molecular drivers.
  • The development of targeted small-molecule inhibitors signifies a new era in FL treatment.
  • These combined advancements position FL treatment at a critical juncture for significant improvement.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...